A Multicenter, Single arm, Open-label, Expansion Study of ONO-7702 and ONO-7703 in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer(ONO-7702/7703-02E)
Latest Information Update: 09 Feb 2022
At a glance
- Drugs Binimetinib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 09 Feb 2022 Planned number of patients changed from 50 to 100.
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
- 21 Dec 2021 New trial record